HIV+Hepatitis Policy Institute

Biden Budget Boosts Domestic HIV Funding & Proposes PrEP and Hepatitis C Programs

HIV+Hep praises President Biden’s FY24 proposed budget for significantly increasing federal funding to end HIV and hepatitis C in the US. Now it is up to Congress to deliver.

See the press release

HIV Organizations File Discrimination Complaints Against North Carolina Blue Cross Blue Shield

HIV+Hep & NCAAN filed ACA discrimination complaints against North Carolina Blue Cross/Blue Shield for placing almost all HIV drugs, including generics like PrEP, on the highest drug tiers. The complaints were filed with the North Carolina Department of Insurance and the US HHS Office of Civil Rights.

See the press release

HIV+Hep releases report detailing funding needed to increase PrEP uptake

The HIV+Hepatitis Policy Institute has released a report modeling the resources needed to fund a national PrEP program to cover the cost of medications, associated labs, and prescriber time for the uninsured along with necessary provider and community outreach to increase uptake, estimating the cost at $521 million for the first year and $6.18 billion over ten years.

See the press release

Patient groups file suit to end policy that prohibits copay assistance from counting toward patients' out-of-pocket spending

The HIV+Hepatitis Policy Insite, the Diabetes Leadership Council, and the Diabetes Patient Advocacy Coalition filed suit in the U.S. District Court for the District of Columbia challenging a federal rule that allows health insurers and pharmacy benefits managers to avoid counting drug manufacturer copay assistance toward patients’ out-of-pocket cost obligations. Due to increased deductibles and cost-sharing requirements, patients rely on copay assistance to help them afford their prescription drugs.

See the press release

Ending Hepatitis is something we can all do every day

“To end infectious diseases, we always need more scientific advances, but it is going to take a strategic, coordinated, & resourced public health response. Fortunately, we now have national strategic plans to end several infectious diseases including viral hepatitis, HIV, & STIs. A strength included in all the plans is a reliance on taking a syndemic approach to these often intersecting epidemics. Together we can get to the finish line faster.”

See the opinion piece

Federal Government Issues Guidance to Insurers on Coverage of HIV Prevention Drugs

The federal government issued guidance to insurers to remind them of their obligation to cover pre-exposure prophylaxis (PrEP), which are drugs that prevent HIV, at no cost to their beneficiaries. The guidance, in the form of an FAQ, also clarifies that associated services with PrEP, such as provider visits and HIV, hepatitis, and STD testing along with other laboratory tests, must also be covered with no patient cost-sharing.

See the press release

Who We Are

Monitors policies that impact the prevention and treatment of HIV, viral hepatitis, and other health conditions in the United States.

Communicates with members of the HIV, hepatitis, and other patient group communities on key policy issues that impact their access to healthcare.

Educates policymakers and members of the media about efforts to end both HIV and hepatitis in the United States and to improve access to quality and affordable healthcare for people with or at risk of serious or chronic health conditions.

Causes We Care About, and So Should You!

HIV

Promote necessary funding, programs, and policies to end the HIV epidemic in the United States

HEPATITIS

Promote necessary funding, programs, and policies to end viral hepatitis in the United States

HEALTHCARE ACCESS

Promote necessary funding, programs, and policies to end viral hepatitis in the United States

Learn More

Facebook posts by @HIV+Hep

HIV and Hepatitis Policy Institute1 day ago

The HIV and Hepatitis Policy Institute testimony urged the House Committee on Appropriations House Appropriations Democrats to ↑ FY24 funding for #HIV & #hepatitis progs: “Our nation can eliminate both HIV & viral hepatitis, but without an infusion of...

View on Facebook

HIV and Hepatitis Policy Institute1 day ago

The next #PACHA meeting is quickly approaching! Join the livestream on March 29 & 30 to share your input on how the Council can address community needs and to hear updates on current PACHA activities. We’ll also be live tweeting throughout from...

View on Facebook

HIV and Hepatitis Policy Institute1 day ago

The state’s lawsuit alleged certain pharmacy-benefit managers shared drug pricing and other information to gain leverage during rebate negotiations with pharmaceutical companies.

View on Facebook

HIV and Hepatitis Policy Institute3 days ago

Youth obesity is an epidemic, but few insurers will cover drugs costing more than $1,300 a month for adolescents.

View on Facebook

HIV and Hepatitis Policy Institute3 days ago

Internal documents and former company executives reveal how Cigna doctors reject patients’ claims without opening their files. “We literally click and submit,” one former company doctor said.

View on Facebook

HIV and Hepatitis Policy Institute4 days ago

https://www.providencejournal.com/story/news/politics/2023/03/23/top-mckee-aide-lobbies-as-private-citizen-for-coverage-of-hiv-prevention-treatment-drugs/70039257007/

Top McKee aide lobbies as private citizen for coverage of HIV prevention, treatment drugs

View on Facebook

Tweets by @HIV+Hep

HIV+Hepatitis Policy Institute · 9 hours ago
@HIVHep

Speaking to @eBARnews @HIVHep’s Carl Schmid highlighted @POTUS’ FY24 proposed budget including a 10-year $9.7b #PrEP delivery prog, $15m to ↑ PrEP at commty health ctrs., & a 5-year $11b prog to combat #hepC: https://t.co/rr3t3myhLF https://t.co/Grfk7lFFRh

View on Twitter

HIV+Hepatitis Policy Institute · 1 day ago
@HIVHep

Ohio has sued some companies that manage drug benefits, saying the firms colluded to gain leverage during drug-rebate negotiations
https://t.co/6RSX1YNn2c via @WSJ

View on Twitter

In reply toHIV+Hepatitis Policy Institute

@HIVHep on the release of @POTUS’ FY24 proposed budget: “It is essential that Congress works together to ensure it maintains the federal govt’s commitment to #endHIV & end #hepatitis,” warning against cutting these life-saving progs as some propose: https://t.co/K1hJVob1x6 https://t.co/YOtw7690lu

View on Twitter

In reply toHIV+Hepatitis Policy Institute

@HIVHep thanks @councilofdc’s Health Cmte. @chenderson @BrianneKNadeau @charlesallen @VinceGrayWard7 @ZacharyforWard5 for voting for the Copay Accumulator Amend. Act of 2023 to ensure #allcopayscount for #patients: https://t.co/NT414S73kA https://t.co/pCPsfCPZhz

View on Twitter

HIV+Hepatitis Policy Institute · 3 days ago
@HIVHep

Their child’s obesity drug was working. Then their plan refused to pay. https://t.co/dkzDvLBuDV

View on Twitter

HIV+Hepatitis Policy Institute · 3 days ago
@HIVHep

For the latest updates on the lawsuit filed by @HIVHep @DiabetesLeaders @DiabetesPAC to ↑ #Rx affordability by ensuring #allcopayscount for #patients, not #insurers & #PBMs, visit: https://t.co/TPoJP1PI57 https://t.co/aMPEmKyFO5

View on Twitter

Biden Budget Boosts Domestic HIV Funding & Proposes PrEP and Hepatitis C Programs

HIV Organizations File Discrimination Complaints Against North Carolina Blue Cross Blue Shield

HIV+Hep releases report detailing funding needed to increase PrEP uptake

Patient groups file suit to end policy that prohibits copay assistance from counting toward patients' out-of-pocket spending

Ending Hepatitis is something we can all do every day

Federal Government Issues Guidance to Insurers on Coverage of HIV Prevention Drugs

Who We Are

HIV

HEPATITIS

HEALTHCARE ACCESS

Facebook posts by @HIV+Hep

HIV and Hepatitis Policy Institute

Tweets by @HIV+Hep

Pin It on Pinterest